中文摘要：

完全性房室传导阻滞是各种心脏病的重要并发症,生物心脏起搏是近年来其治疗研究的热点。本文通过分析目前生物起搏的临床应用所面临的瓶颈和问题,结合笔者的研究实践,就再建心脏房室传导通路这一课题提出如下思考：（1）组织工程化心传导束（ECT）是生物起搏治疗房室传导阻滞策略中一种较为理想的方式;（2）非基因改造成体干细胞诱导为起搏细胞或传导细胞,能够使生物起搏和ECT治疗房室传导阻滞的临床推广应用变得容易;（3）采用ECT实现生理性房室传导及临床应用,必须对其进行传导速度调控;（4）须围绕＂ECT组织细胞类型及缝隙连接蛋白表达＂这一关键点,设计传导速度调控的可行性方案。相信随着ECT研究工作的深入开展,ECT必将对生物起搏治疗的临床转化产生重要影响。

英文摘要：

Complete atrioventricular conduction block,a significant complication of many heart diseases,is a serious threat to human health,and the biological pacemaker is a research focus in this area.In this paper,we discussed the current obstacles of biological pacemaker from laboratory to clinical application and summarized our practice.We put forward the following considerations for establishing a new atrioventricular conduction pathway：（1）engineered conduction tract or tissue（ECT）is a relatively ideal way to treat atrioventricular conduction block with biological pacing;（2）a transgene-independent method for the generating pacemaker or conduction cells from adult stem cells makes it easy for the biological pacemaker or ECT application;（3）the conduction velocity regulation is important to achieve the physiological atrioventricular conduction in clinical application with ECT;and（4）the feasible solutions of regulating the conduction velocity depend on the cell types and connexins expressions in ECT.It is believed that ECT will soon have a significant impact on the clinical transformation of biological pacing application.